Dr. Sacks is Professor of Cardiovascular Disease Prevention in the Nutrition Department of Harvard Chan School of Public Health; Professor of Genetics & Complexes Diseases; and Professor of Medicine at Harvard Medical School. Dr. Sacks led the panel designing the DASH Study, which crafted a healthful eating pattern and demonstrated..
PPAR gamma agonist
Prof. Frank M. Sacks discussing the role that Pioglitazone plays as a relevant #PPAR agonist
Read MorePPAR gamma agonistPPAR alpha delta : what you need to know about the latest results
Prof Sacks, USA reviews the available data about PPAR alpha delta and the Elafibranor clinical program (RESOVE-IT). The interim results were presented earlier this year. They are somewhat disappointing (especially regarding the primary liver outcome).
Read MorePPAR alpha delta : what you need to know about the latest resultsPPAR alpha gamma dual agonists : what you need to know
Prof Sacks, USA reviews the available data about PPAR gamma agonist (Pioglitazone) especially data from the PROACTIVE study published in the Lancet in 2005
Read MorePPAR alpha gamma dual agonists : what you need to knowLipids effects of PPARs by Prof. F. Sacks
Prof Sacks, USA summarises what we know about the PPARs lipid effects. If the strongest evidence is with PPAR-alpha agonists for which the main lipid effect is lowering triglycerids, the are interesting information to discuss about PPAR-delta (Seladelpar).
Read MoreLipids effects of PPARs by Prof. F. SacksThe link between lipids and PPARs in NASH by Prof. F. Sacks
Prof Sacks, Harvard Medical School, discusses the link between PPAR agonists and plasma lipid risk factors for cardiovascular disease. He explains how free fatty acids go to the liver and become lipotoxic. This activates inflammation in the liver which in turn reacts.
Read MoreThe link between lipids and PPARs in NASH by Prof. F. Sacks